183 Persistent MRSA bacteremia 8 87. Rose, W.E.; Fallon, M.; Moran, J.J.M.; Vanderloo, J.P. Vancomycin Tolerance in MethicillinResistant Staphylococcus aureus: Influence of Vancomycin, Daptomycin, and Telavancin on Differential Resistance Gene Expression. Antimicrob. Agents Chemother. 2012, 56, 4422–4427. 88. Britt, N.S.; Patel, N.; Shireman, T.I.; El Atrouni, W.I.; Horvat, R.T.; Steed, M.E. Relationship between vancomycin tolerance and clinical outcomes in Staphylococcus aureus bacteraemia. J. Antimicrob. Chemother. 2016, 72, 535–542. 89. Gonzalez, N.; Sevillano, D.; Alou, L.; Cafini, F.; Gimenez, M.-J.; Gomez-Lus, M.-L.; Prieto, J.; Aguilar, L. Influence of the MBC/MIC ratio on the antibacterial activity of vancomycin versus linezolid against methicillin-resistant Staphylococcus aureus isolates in a pharmacodynamic model simulating serum and soft tissue interstitial fluid concentrations reported in diabetic patients. J. Antimicrob. Chemother. 2013, 68, 2291–2295. 90. Safdar, A.; Rolston, K.V.I. Vancomycin tolerance, a potential mechanism for refractory gram-positive bacteremia observational study in patients with cancer. Cancer 2006, 106, 1815–1820. 91. Levin-Reisman, I.; Ronin, I.; Gefen, O.; Braniss, I.; Shoresh, N.; Balaban, N.Q. Antibiotic tolerance facilitates the evolution of resistance. Science 2017, 355, 826–830. 92. Sader, H.S.; Jones, R.N.; Rossi, K.L.; Rybak, M.J. Occurrence of vancomycin-tolerant and heterogeneous vancomycin-intermediate strains (hVISA) among Staphylococcus aureus causing bloodstream infections in nine USA hospitals. J. Antimicrob. Chemother. 2009, 64, 1024–1028. 93. Moise, P.A.; Sakoulas, G.; Forrest, A.; Schentag, J.J. Vancomycin In Vitro Bactericidal Activity and Its Relationship to Efficacy in Clearance of Methicillin-Resistant Staphylococcus aureus Bacteremia. Antimicrob. Agents Chemother. 2007, 51, 2582–2586. 94. Elgrail, M.M.; Chen, E.; Shaffer, M.G.; Srinivasa, V.; Griffith, M.P.; Mustapha, M.M.; Shields, R.K.; Van Tyne, D.; Culyba, M.J. Convergent Evolution of Antibiotic Tolerance in Patients with Persistent Methicillin-Resistant Staphylococcus aureus Bacteremia. Infect. Immun. 2022, 90, e00001-22. 95. Michaux, C.; Ronneau, S.; Giorgio, R.T.; Helaine, S. Antibiotic tolerance and persistence have distinct fitness trade-offs. PLoS Pathog. 2022, 18, e1010963. 96. McCormick, M.H.; McGuire, J.M.; Pittenger, G.E.; Pittenger, R.C.; Stark, W.M. Vancomycin, a new antibiotic. I. Chemical and biologic properties. Antibiot. Annu. 1955, 3, 606–611. 97. Cong, Y.; Yang, S.; Rao, X. Vancomycin resistant Staphylococcus aureus infections: A review of case updating and clinical features. J. Adv. Res. 2020, 21, 169–176. 98. Shariati, A.; Dadashi, M.; Moghadam, M.T.; van Belkum, A.; Yaslianifard, S.; DarbanSarokhalil, D. Global prevalence and distribution of vancomycin resistant, vancomycin intermediate and heterogeneously vancomycin intermediate Staphylococcus aureus clinical isolates: A systematic review and meta-analysis. Sci. Rep. 2020, 10, 12689. 99. Holland, T.L.; Fowler, V.G. Vancomycin Minimum Inhibitory Concentration and Outcome in Patients with Staphylococcus aureus Bacteremia: Pearl or Pellet? J. Infect. Dis. 2011, 204, 329–331. 100. van Hal, S.J.; Lodise, T.P.; Paterson, D.L. The Clinical Significance of Vancomycin Minimum Inhibitory Concentration in Staphylococcus aureus Infections: A Systematic Review and Meta-analysis. Clin. Infect. Dis. 2012, 54, 755–771.
RkJQdWJsaXNoZXIy MTk4NDMw